Tissue Print Micropeels for Molecular Profiling Cancer

用于癌症分子分析的组织打印显微剥离术

• 批准号: 6862319
• 负责人: SANDRA M GASTON
• 金额: $ 14.62万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-02-01 至 2007-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6862319
• 关键词: breast neoplasms; clinical research; histopathology; human data; human tissue; molecular oncology; polymerase chain reaction; prostate neoplasms; technology /technique development; tissue /cell preparation

DESCRIPTION (provided by applicant): Molecular profiling has emerged as an important strategy for identifying marker "signatures" associated with the biological changes that characterize specific cancers. To realize the full potential of the wealth of new biomarker information, it is essential to develop strategies for profiling human tissue and tumor specimens that are workable in a clinical setting. Clinical specimens are heterogeneous, and tissue heterogeneity is one of the major sources of complexity that must be addressed in the application of molecular profiling to the analysis of human cancers. We have developed a set of novel "tissue print" techniques that allow us to profile the molecular markers over extended areas of human tissue and tumor samples without damaging the specimen. We first applied our new tissue print techniques in the profiling of protein markers associated with capsular invasion in radical prostatectomy specimens. More recently, we have discovered that, during tissue print collection, we can peel a layer of cells off of the specimen and that this process does not cause detectable tissue damage (as determined by surgical pathologists), and thus does not interfere with routine clinical surgical pathology. We have also shown that the cells collected in the tissue print "micropeel" are adequate for PCR and quantitative rt-PCR analysis, allowing us to score multiple molecular markers and assemble the results in "tiling patterns" corresponding to the specimen surface. In the project outlined in this proposal, we will work closely with the research and development team at Qiagen Inc. to optimize the yield of mRNA and DNA from our tissue print micropeels collected from human prostate and breast tissue/tumors specimens. We will then develop a proof-of-principle pilot application of the tissue-print micropeel sampling technique for prostate needle biopsies, one of the classes of specimens that must be conserved intact for clinical diagnosis. Our long term goal is to utilize tissue print techniques in the clinical setting to simplify the process of obtaining an adequate representation of human cancers in biopsies and surgical specimens, and to develop protocols for this tissue sampling platform to support both proteomic analysis and PCR-based DNA and mRNA profiling techniques. In addition to facilitating basic and translational research, the tissue-printing platform can also be utilized as a tool for dedicated clinical applications, to provide "molecular sections" of extended areas of the specimen when the marker profile is itself of potential diagnostic importance.

描述（由申请人提供）：分子谱分析已成为识别与表征特定癌症的生物学变化相关的标记“特征”的重要策略。为了充分发挥新生物标志物信息财富的潜力，制定在临床环境中可行的人体组织和肿瘤标本分析策略至关重要。临床标本是异质性的，组织异质性是复杂性的主要来源之一，必须在分子谱分析应用于人类癌症分析中加以解决。我们已经开发了一套新颖的“组织打印”技术，使我们能够在不损坏标本的情况下对人体组织和肿瘤样本的扩展区域进行分子标记。我们首先将新的组织打印技术应用于根治性前列腺切除术标本中与囊膜侵袭相关的蛋白质标记物的分析。最近，我们发现，在组织指纹收集过程中，我们可以从标本上剥离一层细胞，而且这个过程不会造成可检测到的组织损伤（由外科病理学家确定），因此不会干扰常规的临床外科病理学。我们还表明，组织打印“微皮”中收集的细胞足以进行PCR和定量rt-PCR分析，使我们能够对多个分子标记进行评分，并将结果组装成与标本表面对应的“平铺图案”。